🦠 Group A Streptococcus Vaccine Tracker Dashboard

Updated July 2026. New Phase 1 first-in-human trial — Vaxcyte's VAX-A1: On June 2, 2026, Vaxcyte announced dosing of the first participant in a first-in-human Phase 1 study of VAX-A1, a multi-subunit conjugate GAS vaccine. VAX-A1 combines three conserved protein antigens — C5a peptidase (ScpA), streptolysin O (SLO), and S. pyogenes adhesion and division protein (SpyAD) — with a modified Group A carbohydrate (GACPR) engineered to remove epitopes historically linked to autoimmune complications (acute rheumatic fever/RHD). The two-stage dose-escalation study is being conducted in Australia and assesses safety, tolerability, and antigen-specific immune responses. Group A Strep causes approximately 800 million new cases of illness and more than 600,000 deaths annually worldwide, with no approved vaccine — making this a significant milestone. Global initiatives supporting the GAS vaccine field include the Strep A Vaccine Global Consortium (SAVAC), the Australian Strep A Vaccine Initiative (ASAVI), the WHO PD-VAC, and CARB-X.

Comprehensive tracking of Group A Streptococcus (GAS) vaccine development to prevent strep throat, rheumatic fever, rheumatic heart disease, and invasive streptococcal infections. GAS causes 500,000+ deaths annually, primarily from rheumatic heart disease (319,000 deaths) and invasive infections. No licensed vaccine exists despite century of research. Multiple M-protein based vaccines in Phase 1-3 trials targeting streptococcal pharyngitis, scarlet fever, and autoimmune complications. This tracker monitors 30-valent M-protein vaccines, conserved epitope approaches, and next-generation platforms for GAS prevention.